> WP1302

Graves’ disease is an autoimmune disease in which the immune system attacks the thyroid gland and causes it to become overactive. It causes overproduction of thyroid hormone leading to various symptoms such as, heat intolerance, sweating, weight loss,  and muscle weakness. Thyroid eye disease which manifests as eye bulging is a frequent complication and associated with the potential risk of blindness. Graves' disease is one of the most common autoimmune diseases, with approximately 10 million patients across Europe and the US.  

First line therapies for Graves’ disease consist of anti-thyroid drugs to reduce the production of thyroid hormones and/or radioactive iodine therapy. Many patients often fail current first line therapy and the last remaining option is surgical removal of the thyroid, leading to lifelong thyroid replacement therapy and potential complications such as scarring and vocal cord damage.

Graves' disease provides fast market entry opportunities through rare and serious orphan indications with high unmet medical need including Graves' ophthalmopathy and paediatric Graves' disease.

WP1302 is the first treatment to target the immunological basis of Graves' disease and the first innovative treatment in more than 60 years for patients with the disease. WP1302 has been evaluated in a Phase I study in patients and is showing promising signs of early efficacy in the majority of patients with very favourable safety profile.